Drug Updates

The following information helps you to find FDA Alerts and Pharmacist’s Applications to Practice quickly and easily. In cooperation with the Food and Drug Administration (FDA), and as a service to our members, HOPA distributes information about newly approved therapies for cancer patients from FDA’s Office of Oncology Drug Products Director, Dr. Richard Pazdur to inform oncologists and professionals in oncology-related fields in a timely manner.

Pharmacist at work

Links to product labels will take you to relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, HOPA does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described.

Along with HOPA’s Publications Committee, members also review new drug updates and provide analysis and research on the application of these new drugs or indications. Pharmacist’s Applications to Practice, or PAP, are listed after drugs that include the additional analysis.

  • Current as of: 05/04/2022
    Encorafenib (BRAFTOVI, Array BioPharma Inc.)
  • Current as of: 05/04/2022
    Ripretinib (QINLOCK, Deciphera Pharmaceuticals, LLC.)
  • Current as of: 05/04/2022
    Abatacept (ORENCIA, Bristol-Myers Squibb Company)